Choosing a hospital in China for multiple myeloma: match the team to the treatment phase

A patient may need diagnostic clarification, first-line planning, transplant assessment, relapse treatment or management of complications. A hospital name alone does not identify which service best fits that problem. More useful criteria are the team's ability to interpret the disease, deliver the required treatment and organize continuing care. This guide uses professional guidance and institutional information checked in September 2026. A public service description does not establish individual acceptance, an available bed or a treatment place.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

For an uncertain diagnosis, look for plasma-cell disease expertise and appropriate laboratory and pathology assessment. For someone ready to collect stem cells, examine the transplant pathway. After repeated relapse, the relevant team should analyze resistance and subsequent immunotherapy choices. The EHA–EMN myeloma guideline illustrates why decisions differ across these phases.
A bispecific service needs arrangements for step-up dosing, fever and neurological assessment, infection prevention, immunoglobulin management and restarting after interruptions. Continuing treatment at home may be necessary, so discuss the receiving service before the first dose. The bispecific infection-management consensus explains the continuing-care burden.
Provide the original diagnosis, sequential therapies and responses, current symptoms, recent blood and imaging results, intended treatment phase and available time abroad. Ask which department should receive the case, what additional information is needed and how assessment will proceed. The response should demonstrate an understanding of the actual clinical question.

Quick answer

Full guide

State the problem the visit should resolve

For an uncertain diagnosis, look for plasma-cell disease expertise and appropriate laboratory and pathology assessment. For someone ready to collect stem cells, examine the transplant pathway. After repeated relapse, the relevant team should analyze resistance and subsequent immunotherapy choices. The EHA–EMN myeloma guideline illustrates why decisions differ across these phases.

Summarize the need precisely, for example progression during lenalidomide maintenance with a request to assess the next regimen. Attach the treatment timeline. This helps the institution route the case to a myeloma clinic, transplant service or another consultation. A referral stating only “advanced cancer” omits information that can determine both acceptance and treatment options.

Assess how diagnostic results are interpreted

Myeloma assessment brings together marrow morphology, flow cytometry, genetics, protein studies and imaging. The team should explain which existing results are sufficient, what needs review and how findings change management. Equipment ownership alone does not establish sampling quality, laboratory quality control or clinical interpretation. The IMWG imaging consensus describes the complementary roles of imaging approaches.

For MRD testing, ask about the method, sensitivity, sample adequacy and effect on decisions rather than seeking the word negative in isolation. The IMWG response and MRD standards provide a reference. If follow-up will alternate between countries, agree which tests can be compared so that a method change is not mistaken for a change in disease.

Use institutional information to establish possible consultation routes

An official Peking Union Medical College Hospital specialist profile identifies myeloma expertise, research and longitudinal follow-up work. This supports considering a plasma-cell disease consultation, but does not establish supply of a particular new medicine or appointment availability. Confirm the appropriate clinic, campus and international-patient process through the institution.

Peking University People's Hospital has described its myeloma service and documented collection and transplant facilities in its Tongzhou transplant-unit announcement. This is a potential route for transplant assessment, while the historical announcement cannot confirm current admission arrangements or personal eligibility. A favorable patient example in a hospital story is not an outcome guarantee for another person.

Sun Yat-sen University Cancer Center provides an official hematological-oncology page and an English patient-services page. The latter lists hematological oncology at the Huangpu campus and states that a treatment plan cannot be supplied before arrival in China. These examples are consultation starting points, not a hospital ranking. The appropriate list also depends on the patient's location, clinical needs and practical constraints.

For autologous transplant, examine the complete pathway

Assessment, mobilization and collection, processing and storage, conditioning, infusion and recovery all matter. Asking only whether a center performs transplant is insufficient. Existing renal impairment, poor nutrition or infection should be addressed in the feasibility discussion. The EBMT myeloma chapter explains the clinical components.

Confirm whether collection, admission and follow-up occur on the same campus, and who manages the patient after discharge. If induction is already being delivered reliably at home, discuss when transfer becomes clinically useful rather than assuming an immediate move is necessary. Information exchange between the home hematologist and transplant service can allow preparation to occur without disrupting effective local care.

Verify the cellular product, not only the center's title

CAR-T products differ in target, indication, manufacturing and monitoring requirements. Participation in a research study does not mean a hospital routinely provides every marketed product. Ask for the generic name under consideration, the applicable indication, whether the pathway is investigational and the institution responsible for delivery.

China's National Health Commission anticancer guidance includes myeloma CAR-T entries and operational requirements; the zevorcabtagene entry refers to appropriately assessed institutions and trained staff. Subsequent product updates still need checking. A US earlier-line indication or policy change for another product should not be transferred automatically to a Chinese therapy. Payment alone does not establish a manufacturing place.

Check support for bispecific antibodies and antibody–drug conjugates

A bispecific service needs arrangements for step-up dosing, fever and neurological assessment, infection prevention, immunoglobulin management and restarting after interruptions. Continuing treatment at home may be necessary, so discuss the receiving service before the first dose. The bispecific infection-management consensus explains the continuing-care burden.

If belantamab is proposed, eye assessment is part of the pathway. Medicine supply without timely required monitoring may still prevent reliable delivery. The FDA belantamab information establishes the ocular concern, not access at a Chinese hospital. Ask who coordinates these additional appointments and how results reach the prescribing team.

Match renal, skeletal and emergency support to the patient

Unstable renal function may require joint hematology and nephrology care, prescription adjustment, fluid planning or dialysis. A proposed regimen is incomplete if it does not address the cause and recent trajectory of kidney injury. The IMWG renal recommendations support timely assessment. Acute kidney failure or marked symptoms should be managed locally rather than waiting for replies from every candidate hospital.

Vertebral collapse, long-bone lesions and walking difficulty can require orthopedic, spinal, radiation and rehabilitation input. The IMWG bone recommendations distinguish these roles. Ask whether stabilization should precede another treatment and who supplies activity restrictions. New weakness or bowel and bladder changes need an emergency pathway, not a routine clinic booking.

Interpret institutional outcomes only with their definitions

If a center quotes a success rate, ask about the treatment phase, product, definition and follow-up interval. Short-term response, early transplant safety and long-term survival are different measures. Without the case mix and denominator, a percentage cannot establish that one hospital is preferable for the individual.

A more useful consultation explains the likely benefit for this patient, the main risks, the reassessment point and the alternative if treatment does not proceed as hoped. Unknowns should be tied to missing records or necessary examination. Compare how candidate teams interpret the same resistance history and organ-function information; differing assumptions may explain different recommendations.

Confirm the international-patient service item by item

Ask whether the institution accepts patients with the relevant residence and documentation, which languages records should use and whether interpretation can be booked. An English website does not establish English communication throughout every department. Preliminary file review should not be assumed to constitute final acceptance or a prescription.

Choose accommodation for the actual treatment campus, not simply the main hospital address. Transfers between campuses, accessible transport, caregiver arrangements and emergency admission can affect daily feasibility. Oxygen, dialysis and fracture precautions require specific preparation before travel. A general transport or coordination service cannot by itself provide those medical arrangements.

Compare costs together with continuing-care responsibilities

Request RMB estimates for the same treatment phase, separating investigations, medicine, administration, admission, specialist monitoring and follow-up. For transplant or cellular therapy, ask how extra mobilization, bridging treatment, infection or prolonged observation is billed. No individual hospital price has been verified here, and equipment numbers do not indicate the eventual bill.

Establish who will take over after return. The home physician needs the response, complications, actual administrations and next steps. If a proposed pathway requires a stay in China that the patient cannot sustain, a favorable short-term quotation does not resolve the problem. Treatment selection and continuing-care planning should occur together.

Use a prepared consultation to narrow the options

Provide the original diagnosis, sequential therapies and responses, current symptoms, recent blood and imaging results, intended treatment phase and available time abroad. Ask which department should receive the case, what additional information is needed and how assessment will proceed. The response should demonstrate an understanding of the actual clinical question.

The final choice should reflect disease needs, available treatment, monitoring and the patient's life constraints. A stable patient may combine specialist advice with ongoing local therapy, while someone needing complex procedures should enter an appropriate service at the clinically relevant time. The hospital list is only the beginning; the practical result is a care pathway that remains workable when health or treatment plans change.